Developing patient-centric medicines for older people : Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population
© 2020 The British Pharmacological Society..
Increased global longevity requires a re-evaluation of current structures in society to adapt to the consequential demographic shift. As (very) old people are prone to impaired human organ and body functions resulting in, for example, multimorbidity, polypharmacy, hospitalisation and problems in medication management, it is increasingly acknowledged that re-evaluations should include the suitability of pharmaceutical patient care as one of the cornerstones of public health. Following the 2011 European Medicines Agency (EMA) Geriatric Strategy, in 2017 the EMA published the draft "Reflection paper on the pharmaceutical development of medicines for use in the older population". The draft paper was opened for public consultation and specific attention and feedback (either supportive or with a proposal for revision) was asked on three design aspects: tablet breaking, drug administration through enteral feeding tubes and medication management. Following publication, the draft paper was presented at two public conferences attended by participants from different disciplines. This manuscript is intended to draw the attention of different stakeholder parties to the urgent need to collaborate on the emerging issues arising from increasing longevity and multimorbidity, and especially those associated with pharmaceutical patient care and drug product design, including the need for collaborative research into existing or emerging knowledge gaps. The manuscript focuses on the three aforementioned aspects of pharmaceutical development (tablet breaking, drug administration through enteral feeding tubes and medication management) as these highly relate to medication safety and efficacy and constitute persistent and typical challenges for older people, caregivers and healthcare professionals in daily clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 86(2020), 10 vom: 15. Okt., Seite 2008-2013 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Riet-Nales, Diana A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.07.2021 Date Revised 02.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.14530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314039473 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314039473 | ||
| 003 | DE-627 | ||
| 005 | 20231225151854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14530 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314039473 | ||
| 035 | |a (NLM)32830323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Riet-Nales, Diana A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Developing patient-centric medicines for older people |b Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2021 | ||
| 500 | |a Date Revised 02.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The British Pharmacological Society. | ||
| 520 | |a Increased global longevity requires a re-evaluation of current structures in society to adapt to the consequential demographic shift. As (very) old people are prone to impaired human organ and body functions resulting in, for example, multimorbidity, polypharmacy, hospitalisation and problems in medication management, it is increasingly acknowledged that re-evaluations should include the suitability of pharmaceutical patient care as one of the cornerstones of public health. Following the 2011 European Medicines Agency (EMA) Geriatric Strategy, in 2017 the EMA published the draft "Reflection paper on the pharmaceutical development of medicines for use in the older population". The draft paper was opened for public consultation and specific attention and feedback (either supportive or with a proposal for revision) was asked on three design aspects: tablet breaking, drug administration through enteral feeding tubes and medication management. Following publication, the draft paper was presented at two public conferences attended by participants from different disciplines. This manuscript is intended to draw the attention of different stakeholder parties to the urgent need to collaborate on the emerging issues arising from increasing longevity and multimorbidity, and especially those associated with pharmaceutical patient care and drug product design, including the need for collaborative research into existing or emerging knowledge gaps. The manuscript focuses on the three aforementioned aspects of pharmaceutical development (tablet breaking, drug administration through enteral feeding tubes and medication management) as these highly relate to medication safety and efficacy and constitute persistent and typical challenges for older people, caregivers and healthcare professionals in daily clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a European Medicines Agency (EMA) | |
| 650 | 4 | |a aged 80 and over [MeSH] | |
| 650 | 4 | |a clinical pharmacology, drug regulation | |
| 650 | 4 | |a clinical pharmacology, health policy | |
| 650 | 4 | |a clinical pharmacology, medication safety | |
| 650 | 4 | |a drug development, drug delivery | |
| 650 | 4 | |a medication errors [MeSH] | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a regulations | |
| 650 | 4 | |a technology pharmaceutical [MeSH] | |
| 650 | 7 | |a Tablets |2 NLM | |
| 700 | 1 | |a Sundberg, Katarina |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Anthonius |e verfasserin |4 aut | |
| 700 | 1 | |a Hirschlérova, Blanka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 86(2020), 10 vom: 15. Okt., Seite 2008-2013 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2020 |g number:10 |g day:15 |g month:10 |g pages:2008-2013 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14530 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2020 |e 10 |b 15 |c 10 |h 2008-2013 | ||